查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790280

照護現場診斷分子診斷市場規模、佔有率和趨勢分析報告：按應用、技術、測試地點、最終用途、地區和細分市場預測，2025 年至 2033 年

Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

照護現場分子診斷市場概況

預計2024年全球照護現場診斷市場規模將達82.2億美元，2033年將達到144.7億美元，2025年至2033年的複合年成長率為6.52%。該市場專注於在患者附近進行快速且準確的分子檢測，以便及時做出臨床決策。這些平台的應用範圍廣泛，包括感染疾病檢測、呼吸系統疾病和性行為感染傳染病等。

市場成長的動力源於對分散式檢查日益成長的需求，尤其是在資源有限和重症監護環境中。日益加重的感染疾病負擔以及對快速週轉時間的需求，推動了照護現場技術的廣泛應用。微流體、等溫擴增和攜帶式PCR系統等技術進步正在提高這些診斷方法的準確性和易用性。此外，快速反應檢測作為疫情後醫療保健重點日益受到重視，這也進一步推動了市場擴張。

此外，基層醫療機構中的即時分子診斷涵蓋從簡單的血糖檢測到複雜的血液凝固檢驗等各種檢測。在一些診所，專家已從傳統的實驗室檢測轉向即時檢測，從而避免了檢體製備和運輸過程中的延誤，從而有助於縮短確定是否需要進一步檢測的時間。即時分子診斷的其他優點包括更快獲得結果、更低的成本和更好的療效。近年來，即時分子診斷產業發展迅速，尤其是在美國和歐洲國家，這得益於人們對各種問題的認知不斷提高，包括即時檢測的醫療和組織挑戰以及經濟效益。

老齡化受到多種環境和遺傳因素交互作用的影響，被認為是癌症發展的最重要風險因素。根據美國國家癌症研究所的監測、流行病學和最終結果 (SEER)資料庫，估計有 38% 的女性和 43% 的男性在其一生中會罹患癌症。近三分之二的新癌症病例是在 65 歲或以上的人群中診斷出來的，這表明老齡化成長會導致癌症的可能性增加。分子診斷起著至關重要的作用，因為它對癌症、感染疾病和心血管疾病的管理有顯著的影響。因此，它對於公共衛生監測和檢測至關重要。因此，老年人口的增加預計將推動市場成長。

此外，市場相關人員正在不斷開發新的即時檢測產品，以抓住市場機會。例如，2023年2月，Huwel Lifesciences設計了一款用於病毒分型的可攜式RT-PCR設備。該公司聲稱，該檢測大約需要30分鐘，可用於透過血液或胃腸道樣本檢測感染疾病和其他感染疾病。此外，2023年4月，Curative, Inc.宣布分拆Sensible Diagnostics，專注於商業化一款新的即時檢測PCR平台，該平台可在10分鐘內提供高精度結果。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素
    • 對快速和分散檢測的需求不斷成長
    • 感染疾病率上升
    • 分子平台的技術進步
  • 市場限制因素分析
    • 分子 POC 設備和耗材高成本
    • 監管和品質保證挑戰
  • 商業環境分析
    • 依因素（政治/法律、經濟/技術）進行 SWOT 分析
    • 波特五力分析
    • COVID-19影響分析

第4章 技術業務分析

  • 照護現場分子診斷市場：技術變革分析
  • 基於PCR
    • 2021-2033年市場
  • 依基因序列
    • 2021-2033年市場
  • 雜交基地
    • 2021-2033年市場
  • 基於微陣列
    • 2021-2033年市場

第5章：應用業務分析

  • 照護現場分子診斷市場：應用差異分析
  • 感染疾病
    • 感染疾病市場，2021-2033年
    • HIV POC
    • 困難梭狀芽孢桿菌POC
    • HBV POC
    • 肺炎或鏈球菌感染疾病
    • 呼吸道融合細胞病毒(RSV) 臨床驗證
    • HPV POC
    • 流感/流感 POC
    • HCV POC
    • MRSA POC
    • 結核病和抗藥性結核病的即時治療
    • HSV POC
    • 其他感染疾病
  • 腫瘤學
    • 2021-2033年市場
  • 血液學
    • 2021-2033年市場
  • 產前檢查
    • 2021-2033年市場
  • 內分泌學
    • 2021-2033年市場
  • 其他
    • 2021-2033年市場

第6章 測試地點業務分析

  • 照護現場分子診斷市場：偵測地點差異分析
  • OTC
    • 2021-2033年市場
  • POC
    • 2021-2033年市場

第7章最終用途業務分析

  • 照護現場分子診斷市場：最終用途變異分析
  • 分散式實驗室
    • 2021-2033年市場
  • 醫院
    • 2021-2033年市場
  • 居家醫療
    • 2021-2033年市場
  • 輔助醫療設施
    • 2021-2033年市場
  • 其他
    • 2021-2033年市場

第8章區域業務分析

  • 2024 年及 2033 年 POC 分子診斷市場佔有率（按地區）
  • 北美洲
    • 2021-2033年北美照護現場分子診斷市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲照護現場分子診斷市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區照護現場分子診斷市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2021-2033年拉丁美洲照護現場分子診斷市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2021-2033 年中東和非洲照護現場分子診斷市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與企業概況
  • 參與企業
    • 市場領導者
    • 照護現場分子診斷市場佔有率分析（2023年）
    • 公司簡介
    • 戰略地圖
Product Code: 978-1-68038-886-2

Point-of-Care Molecular Diagnostics Market Summary

The global point of care molecular diagnostics market size was estimated at USD 8.22 billion in 2024 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. This market focuses on rapid and accurate molecular testing conducted near the patient, enabling timely clinical decision-making. These platforms are used across various applications, particularly in infectious disease detection, respiratory illnesses, and sexually transmitted infections.

Market growth is driven by the rising demand for decentralized testing, especially in resource-limited settings and emergency care environments. The increasing burden of infectious diseases and the need for rapid turnaround time have expanded the adoption of point-of-care molecular technologies. Technological advances in microfluidics, isothermal amplification, and portable PCR systems are enhancing the accuracy and usability of these diagnostics. In addition, post-pandemic healthcare priorities emphasize rapid response testing, further supporting market expansion.

Moreover, POC molecular diagnostics in primary care settings range from simple glucose testing to complex coagulation testing. In several clinics, professionals are switching to POC testing from conventional lab testing, which helps shorten the time taken to decide whether further tests are required by avoiding delays during specimen preparation and transport. Other advantages of POC molecular diagnostics are rapid availability of results, lower costs, and better outcomes. The point of care molecular diagnostics industry has grown rapidly in the past few years, especially in the U.S. and European countries, owing to increased awareness regarding various issues such as medical & organizational concerns and economic advantages of POCT.

Aging is influenced by the interaction of several environmental and genetic factors and is characterized as the single most substantial risk factor for cancer development. Based on the U.S. National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in people aged 65 and above, which highlights that aging can make people more vulnerable to cancer. This is where molecular diagnostics play an important role, as it has a tremendous impact on the management of cancer, infectious diseases, and cardiovascular diseases. It is, therefore, vital for public health surveillance and detection. Thus, the growing geriatric population is expected to drive market growth.

Moreover, market players are continuously involved in the development of novel POC testing products to capitalize on market opportunities. For instance, in February 2023, Huwel Lifesciences designed a portable RT-PCR machine to test types of viruses. The company claimed that the test takes around 30 minutes and can be used to detect respiratory and other infections using blood and gastrointestinal samples. Moreover, in April 2023, Curative, Inc. announced the spin-off of Sensible Diagnostics, focusing on the commercialization of a novel POC PCR testing platform to provide results within 10 minutes with high accuracy.

Global Point Of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global point of care molecular diagnostics market report based on application, technology, test location, end-use, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
    • HIV POC
    • Clostridium difficile POC
    • HBV POC
    • Pneumonia or Streptococcus associated infections
    • Respiratory syncytial virus (RSV) POC
    • HPV POC
    • Influenza/Flu POC
    • HCV POC
    • MRSA POC
    • TB and drug-resistant TB POC
    • HSV POC
    • Other Infectious Diseases
  • Oncology
  • Hematology
  • Prenatal Testing
  • Endocrinology
  • Other Applications
  • Test Location Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • POC
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Growing Demand for Rapid and Decentralized Testing
    • 3.4.2. Rising Prevalence of Infectious Diseases
    • 3.4.3. Technological Advancements in Molecular Platforms
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Molecular POC Devices and Consumables
    • 3.5.2. Regulatory and Quality Assurance Challenges
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based Market, 2021 - 2033 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based Market, 2021 - 2033 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC Market, 2021 - 2033 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC Market, 2021 - 2033 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC Market, 2021 - 2033 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC Market, 2021 - 2033 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC Market, 2021 - 2033 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology Market, 2021 - 2033 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology Market, 2021 - 2033 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC Market, 2021 - 2033 (USD Million)
  • 6.3. POC
    • 6.3.1. POC Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 7.4. Homecare
    • 7.4.1. Home-care Market, 2021 - 2033 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Point-of-Care Molecular Diagnostics Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Abbott
        • 9.3.3.1.1. Company Overview
        • 9.3.3.1.2. Financial Performance
        • 9.3.3.1.3. Product Benchmarking
        • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Bayer AG
        • 9.3.3.2.1. Company Overview
        • 9.3.3.2.2. Financial Performance
        • 9.3.3.2.3. Product Benchmarking
        • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. F. Hoffmann-La Roche AG
        • 9.3.3.3.1. Company Overview
        • 9.3.3.3.2. Financial Performance
        • 9.3.3.3.3. Product Benchmarking
        • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Nova Biomedical
        • 9.3.3.4.1. Company Overview
        • 9.3.3.4.2. Financial Performance
        • 9.3.3.4.3. Product Benchmarking
        • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. QIAGEN
        • 9.3.3.5.1. Company Overview
        • 9.3.3.5.2. Financial Performance
        • 9.3.3.5.3. Product Benchmarking
        • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Nipro Diagnostics
        • 9.3.3.6.1. Company Overview
        • 9.3.3.6.2. Financial Performance
        • 9.3.3.6.3. Product Benchmarking
        • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Danaher
        • 9.3.3.7.1. Company Overview
        • 9.3.3.7.2. Financial Performance
        • 9.3.3.7.3. Product Benchmarking
        • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Bio-Rad Laboratories, Inc.
        • 9.3.3.8.1. Company Overview
        • 9.3.3.8.2. Financial Performance
        • 9.3.3.8.3. Product Benchmarking
        • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. bioMerieux
        • 9.3.3.9.1. Company Overview
        • 9.3.3.9.2. Financial Performance
        • 9.3.3.9.3. Product Benchmarking
        • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Agilent Technologies, Inc.
        • 9.3.3.10.1. Company Overview
        • 9.3.3.10.2. Financial Performance
        • 9.3.3.10.3. Product Benchmarking
        • 9.3.3.10.4. Strategic Initiatives
      • 9.3.3.11. Abaxis
        • 9.3.3.11.1. Company Overview
        • 9.3.3.11.2. Financial Performance
        • 9.3.3.11.3. Product Benchmarking
        • 9.3.3.11.4. Strategic Initiatives
      • 9.3.3.12. OraSure Technologies
        • 9.3.3.12.1. Company Overview
        • 9.3.3.12.2. Financial Performance
        • 9.3.3.12.3. Product Benchmarking
        • 9.3.3.12.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • Table 1. Point-of-care Molecular Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • Table 2. Global Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 3. Global Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 4. Global Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 5. Global Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 6. Global Point-of-care Molecular Diagnostics Market, by region, 2021 - 2033 (USD Million)
  • Table 7. Point-of-care Molecular Diagnostics- Key market driver analysis
  • Table 8. Point-of-care Molecular Diagnostics- Key market restraint analysis
  • Table 9. North America Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 10. North America Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 11. North America Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 12. North America Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 13. North America Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 14. U.S. Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 15. U.S. Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 16. U.S. Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 17. U.S. Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 18. Canada Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 19. Canada Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 20. Canada Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 21. Canada Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 22. Mexico Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 23. Mexico Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 24. Mexico Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 25. Mexico Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 26. Europe Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 27. Europe Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 28. Europe Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 29. Europe Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 30. Europe Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 31. Germany Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 32. Germany Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 33. Germany Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 34. Germany Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 35. UK Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 36. UK Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 37. UK Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 38. UK Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 39. France Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 40. France Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 41. France Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 42. France Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 43. Italy Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 44. Italy Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 45. Italy Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 46. Italy Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 47. Spain Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 48. Spain Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 49. Spain Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 50. Spain Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 51. Denmark Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 52. Denmark Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 53. Denmark Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 54. Denmark Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 55. Sweden Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 56. Sweden Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 57. Sweden Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 58. Sweden Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 59. Norway Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 60. Norway Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 61. Norway Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 62. Norway Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 63. Asia Pacific Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 64. Asia Pacific Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 65. Asia Pacific Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 66. Asia Pacific Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 67. Asia Pacific Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 68. Japan Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 69. Japan Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 70. Japan Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 71. Japan Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 72. China Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 73. China Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 74. China Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 75. China Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 76. India Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 77. India Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 78. India Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 79. India Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 80. Australia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 81. Australia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 82. Australia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 83. Australia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 84. South Korea Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 85. South Korea Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 86. South Korea Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 87. South Korea Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 88. Thailand Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 89. Thailand Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 90. Thailand Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 91. Thailand Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 92. Latin America Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 93. Latin America Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 94. Latin America Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 95. Latin America Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 96. Latin America Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 97. Brazil Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 98. Brazil Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 99. Brazil Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 100. Brazil Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 101. Argentina Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 102. Argentina Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 103. Argentina Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 104. Argentina Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 105. MEA Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 106. MEA Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 107. MEA Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 108. MEA Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 109. MEA Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 110. South Africa Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 111. South Africa Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 112. South Africa Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 113. South Africa Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 114. Saudi Arabia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 115. Saudi Arabia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 116. Saudi Arabia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 117. Saudi Arabia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 118. UAE Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 119. UAE Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 120. UAE Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 121. UAE Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 122. Kuwait Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 123. Kuwait Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 124. Kuwait Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 125. Kuwait Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Point-Of-Care Molecular Diagnostics Market Segmentation
  • Fig. 2 Global Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 3 Point-Of-Care Molecular Diagnostics Market Dynamics
  • Fig. 4 Key Opportunities Prioritized, 2018
  • Fig. 5 Point-Of-Care Molecular Diagnostics Market - Porter's Analysis
  • Fig. 6 Point-Of-Care Molecular Diagnostics Market - PESTEL Analysis
  • Fig. 7 Point-Of-Care Molecular Diagnostics Revenue Share, By Application, 2024 & 2033
  • Fig. 8 POC Mdx Infectious Diseases Market, 2021 - 2033 (USD Million)
  • Fig. 9 POC Mdx Oncology Market, 2021 - 2033 (USD Million)
  • Fig. 10 POC Mdx Hematology Market, 2021 - 2033 (USD Million)
  • Fig. 11 POC Mdx Prenatal Testing Market, 2021 - 2033 (USD Million)
  • Fig. 12 POC Mdx Endocrinology Market, 2021 - 2033 (USD Million)
  • Fig. 13 POC Mdx Other Applications Market, 2021 - 2033 (USD Million)
  • Fig. 14 Point-Of-Care Molecular Diagnostics Revenue Share, By Technology, 2024 & 2033
  • Fig. 15 POC Mdx PCR-Based Market, 2021 - 2033 (USD Million)
  • Fig. 16 POC Mdx Genetic Sequencing-Based Market, 2021 - 2033 (USD Million)
  • Fig. 17 POC Mdx Hybridization-Based Market, 2021 - 2033 (USD Million)
  • Fig. 18 POC Mdx Microarray-Based Market, 2021 - 2033 (USD Million)
  • Fig. 19 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2024 & 2033
  • Fig. 20 POC Mdx Over-The-Counter Market, 2021 - 2033 (USD Million)
  • Fig. 21 POC Mdx Point-Of-Care Market, 2021 - 2033 (USD Million)
  • Fig. 22 Point-Of-Care Molecular Diagnostics Revenue Share, By End Use, 2024 & 2033
  • Fig. 23 POC Mdx Decentralized Labs Market, 2021 - 2033 (USD Million)
  • Fig. 24 POC Mdx Hospitals Market, 2021 - 2033 (USD Million)
  • Fig. 25 POC Mdx Home-Care Market, 2021 - 2033 (USD Million)
  • Fig. 26 POC Mdx Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
  • Fig. 27 POC Mdx Other Uses Market, 2021 - 2033 (USD Million)
  • Fig. 28 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2024 & 2033
  • Fig. 29 POC Mdx OTC Market, 2021 - 2033 (USD Million)
  • Fig. 30 POC Mdx POC Market, 2021 - 2033 (USD Million)
  • Fig. 31 Point-Of-Care Molecular Diagnostics Revenue Share, By Region, 2024 & 2033
  • Fig. 32 North America Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 33 US Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 38 UK Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 39 France Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Denmark Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 45 Asia Pacific Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 46 Japan Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 47 China Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 48 India Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Australia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 50 South Korea Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 51 Thailand Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 52 Latin America Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 53 Brazil Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 54 Argentina Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 55 MEA Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 56 South Africa Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 57 Saudi Arabia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 58 UAE Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 59 Kuwait Point-Of-Care Molecular Diagnostics Market, 2021 - 2033(USD Million)